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Abstract
Background: Liver resection is the only potentially curative treatment for colorectal liver metastases (LM). It is
considered a safe procedure, but is often associated with blood loss during liver transection. Blood transfusions are
frequently needed, but they are associated with increased morbidity and risk of recurrence. Many surgical devices
have been developed to decrease blood loss. However, none of them has proven superior to the standard crushing
technique. We developed a new, powerful intra-operative high-intensity focused ultrasound (HIFU) transducer which
destroys tissue by coagulative necrosis. We aim to evaluate whether HIFU-assisted liver resection (HIFU-AR) results in
reduced blood loss.
Methods: This is a prospective, single-centre, randomized (1:1 ratio), comparative, open-label phase II study. Patients
with LM requiring a hepatectomy for≥ 2 segments will be included. Patients with cirrhosis or sinusoidal obstruction
syndrome with portal hypertension will be excluded. The primary endpoint is normalized blood loss in millilitres per
square centimetre of liver section plane. Secondary endpoints are: total blood loss, transection time, transection time
per square centimetre of liver area, haemostasis time, clip density on the liver section area, rate and duration of the
Pringle manœuvre, rate of patients needing a blood transfusion, length of hospital stay, morbidity, patients with positive
resection margin, and local recurrence. Assuming a blood loss of 7.6 ± 3.7 mL/cm2 among controls, the study will have
85% power to detect a twofold decrease of blood loss in the experimental arm, using a Wilcoxon (Mann-Whitney)
rank-sum test with a 0.05 two-sided significance level. Twenty-one randomized patients per arm are required.
Considering the risk of contraindications at surgery, up to eight patients may be enrolled in addition to the 42
planned, with an enrolment period of 24 months. Randomization will be stratified by surgeon.
Discussion: We previously demonstrated the safety and efficacy of intra-operative HIFU in patients operated on for LM.
We also demonstrated the efficacy of HIFU-AR in a preclinical study. Participants in the HIFU-AR group of this randomized
trial can expect to benefit from reduced blood loss and decreased ischemia of liver parenchyma.
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Background
Medical and scientific context
Patients with most solid tumours may develop liver me-
tastases (LM). However, LM occur mainly in patients with
colorectal cancer (CRC). In France, CRC is the second
most frequent cancer, with an incidence of nearly 41,000
cases each year. It continues to have a poor prognosis and
causes nearly 16,000 deaths per year, often due to LM.
Hepatic resection is the mainstay of treatment for LM and
remains the only potentially curative intervention.
Unfortunately, LM resections are complex major pro-
cedures and the resulting blood loss may be significant,
leading to the requirement for blood transfusions during
the procedure. Such transfusions are correlated with
increased morbidity, mortality and risk of tumour recur-
rence [1–4]. Therefore, the control of blood loss is
mandatory to limit morbidity, mortality and recurrence.
Since the hepatic parenchyma tolerates ischemia better
than bleeding, intra-operative manœuvres have been
proposed to minimize the risk of bleeding during hepatic
resection. These include total vascular exclusion, the
Pringle manœuvre and selective ligature to control
hepatic inflow [5–10]. None of these methods is universally
practical or completely effective, and each carries a risk of
inducing liver dysfunction in patients with chronic liver
disease. Vascular clamping is a time-critical technique, since
the risk of morbidity is increased if clamping lasts more
than 60 continuous minutes.
Overview of high-intensity focused ultrasound (HIFU)
HIFU is mechanical waves generated by an ultrasound
transducer. As with conventional ultrasound, HIFU can
propagate harmlessly through living tissue. However, if
the ultrasound beam carries sufficient energy and is
brought into a tight focus, the energy within the focal
volume can cause a local rise in temperature of sufficient
magnitude (up to 80 °C) to generate irreversible cell
death. This occurs in a few seconds through coagulative
necrosis without damaging the surrounding tissue.
HIFU offers several advantages, which encourage its
clinical development. First, HIFU allows non-invasive
real-time targeting using sonography. Such real-time
monitoring enables adjustment of treatment plans.
Second, the mechanism of action of HIFU is not
tumour-specific; therefore a wide range of tumour types
can be targeted. Third, HIFU is mechanical waves, there-
fore there is no ionizing radiation. Treatment can be
given more than once, as there is no upper limit of
tissue tolerance to repeated ultrasound exposure. Finally,
HIFU generates very few side effects, and serious adverse
events are rare [11]. In several centres worldwide, HIFU
has been in clinical use for 5 to 10 years, sometimes in
daily practice, to treat solid tumours (both malignant
and benign), including those of the prostate [12], liver
[13, 14], breast [15] and kidney [16]. Current data are
encouraging and the role of HIFU in oncology is likely
to expand as devices become more widely available.
However, several technical limitations of currently
available HIFU devices have been raised, such as the
long time needed to treat tumours of several cubic centi-
metres. For example, the sonication time (defined as the
time from the first to the last sonication) to ablate
abdominal pathologies such as uterine leiomyomas with
target volumes of 4.6 cm3 ranged from 32 to 135 minutes
[17, 18]. The use of an extracorporeal HIFU device is
clinically feasible for the treatment of hepatocellular
carcinoma [13, 19] but only a small part (approximately
30%) of the liver is accessible using a non-invasive HIFU
device. In addition, phase aberration and liver movements
can produce secondary lesions (such as skin burns or
gastric lesions) if a completely extracorporeal treatment is
performed. To fill these technical gaps, we undertook a
research program on CRC LM treatment by HIFU.
The HIFU toroidal device: intra-operative HIFU prototype
We previously developed a toroidal HIFU transducer that
enables the destruction of large volumes of tissue over
short periods of time [20]. This work led to the develop-
ment of a prototype that has been tested in vitro and in
preclinical studies. These studies demonstrated the safety
and efficacy of treating the liver using HIFU generated by
a toroidal transducer [21–26]. A collaboration with the
EDAP TMS company has allowed a prototype to be devel-
oped for clinical use and this is currently being evaluated
for the treatment of colorectal LM [27].
The HIFU probe is brought into contact with the liver
using a sterile ultrasound cooling and coupling liquid
(Ablasonic®, EDAP TMP, Vaulx en Velin, France) con-
tained in a sterile polyurethane envelope (Civco, Kalona,
IA, USA). It is possible to change the location of the
focal zone by adjusting the quantity of coupling liquid
between the device and tissues or by electronic focusing.
Under these conditions, the focal zone can be placed
anywhere between the surface of the liver and 9 cm in
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depth. This allows treatment of the entire plane of liver
transection. A 7.5 MHz ultrasound imaging probe
(Vermon, Tours, France) is placed in the centre of the
device and connected to a BK HAWK 2102 EXL scanner
(BK Medical, Herlev, Denmark) to guide the liver resec-
tion. Specific software is used to define the treatment
zone from a two-dimensional ultrasound image. The
user interface displays the position of the HIFU-treated
region superimposed on the sonogram obtained by the
integrated ultrasound imaging probe. It is therefore
possible to locate the ablation and visualize in real time
the treated zone created during ultrasound exposures.
Previous clinical results
Our team has already demonstrated the safety and feasi-
bility of HIFU for intra-operative ablation of liver paren-
chyma. We have also demonstrated in an animal study
that HIFU can be used to assist hepatic resection.
The HIFU device using a toroidal HIFU transducer
guided by ultrasound imaging was evaluated clinically
for the treatment of colorectal LM during an open
procedure. The transducer has a toroidal shape with a
diameter of 70 mm and is divided into 256 emitters each
of 0.13 cm2. The radius of curvature is 70 mm to enable
treatment of the deepest regions of the liver. The operat-
ing frequency is 3 MHz.
We conducted a prospective, single-centre phase I–IIa
trial [27]. HIFU was delivered immediately before sched-
uled hepatectomy. To demonstrate the safety and efficacy
of rapidly ablating large liver volumes, ablations were
performed on healthy tissue within the areas scheduled
for resection. In total, 30 ablations (one superficial and
one at least 1 cm deep) were carried out in 15 patients.
These ablations were all generated within 40 seconds and
on average measured 27.5 × 21 mm. The phase I element
of the study (n = 6) showed that use of the HIFU device
was feasible and safe, and did not damage neighbouring
tissue. The phase IIa study (n = 9) showed both that the
area of ablation could be precisely targeted on a previously
implanted metallic mark and that ablations could be
undertaken deliberately to avoid such a mark. Ablations
were achieved with a precision of 1–2 mm.
These results enable us to conduct a randomized
phase II trial to evaluate whether HIFU-assisted liver re-
section (HIFU-AR) reduces blood loss compared to
standard liver resection in patients with LM.
Methods/Design
Objectives
The primary objective is to compare the blood loss
during hepatectomy in patients treated by HIFU-AR
(arm A) versus standard liver resection (arm B).
The primary endpoint is normalized blood loss in
millilitres/square centimetres, defined as total blood loss
(in millilitres) divided by the resected hepatic surface (in
square centimetres). Total blood loss will be measured
during the whole liver transection procedure, i.e. be-
tween beginning the section of liver parenchyma and the
end of resection including complete haemostasis of the
raw surface of the remaining liver. In arm A, time
needed to perform HIFU pre-coagulation will be added
to this duration. Of note, blood loss is systematically de-
termined by weighing all blood-soaked surgical mops
(PB1502, Mettler Toledo, Columbus, OH, USA) and the
aspirated fluid (blood suctioned out of the abdomen) on
a high-precision scientific scale.
In both arms, the secondary endpoints are:
 transection time (minutes) defined as the time
required to achieve the liver transection (minutes)
and the transection time per surface of resected liver
area (minutes/square centimetres);
 haemostasis time (minutes), defined as the time lapse
between the end of transection until completion of
haemostasis (minutes);
 clip density on the section area, defined as the total
number of haemostatic clips used to perform
haemostasis on the liver section area divided by
the raw surface of the remaining liver (in square
centimetres) (number of clips per square centimetre
of liver area);
 rate and duration of the Pringle manœuvre, defined
as the number of patients requiring Pringle’s manœuvre
during the operating procedure [if blood loss > 500 mL
during the transection, measured through the suction
device, the surgeon will be authorized to perform a
hepatic pedicular clamping (Pringle’s manœuvre)];
 rate of patients needing a blood transfusion, defined
as the number of patients requiring blood transfusions
either during the operation or after it (per-operative
transfusion will be required for patients with blood
loss > 1000 mL; post-operative transfusion will be
required if Hb <8 g/dL or 10 g/dL if previous history
of coronary disease or stroke);
 duration of hospital stay (days), calculated from D0
(date of surgery) to the end of hospitalization
post-surgery;
 safety and tolerability assessed using the Dindo-
Clavien classification specific to surgical complica-
tions. During the first 10 days after surgery, we will
collect data on haemoglobin, platelets, alanine amino-
transferase (ALT), aspartate amino-transferase (AST),
gamma-glutamyltransferase (GGT), prothrombin time
(PT) and total bilirubin values;
 the proportion of patients with malignant
tumours who have a positive resection margin
and patients with local recurrence (from
randomization to M6).
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Study design
This is a prospective, single-centre, randomized, compara-
tive, open-label, phase II study to evaluate the efficacy and
the safety of HIFU-AR, using the device described, during
an open liver resection in patients with LM.
Patients will be randomized 1:1 to either:
 arm A (experimental arm): pre-coagulation by
HIFU-AR plus standard surgical liver resection
 arm B (control arm): standard surgical liver
resection.
The randomization will be performed via an Inter-
net platform in the operating room and will be strati-
fied by surgeon (AD, MR, or PP) to ensure equal
allocation of subgroups of participants (i.e. to each
surgeon) in each arm.
The flowchart is represented in Fig. 1. The Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) checklist can be found in Additional file 1.
Study population
Inclusion and exclusion criteria are listed in Table 1.
Study medical device
The study device is the HIFU prototype from the EDAP
TMS company. Currently, this device has no CE mark
and is restricted to clinical trials.
The HIFU system is composed of three parts:
– a sterilisable probe, manually brought into contact
with the liver, and its accessories (sterile envelope
and O-ring seal);
– a treatment module including electrical signal
generation and treatment control systems. HIFU
exposures are activated using a foot pedal.
– LivKit: single-use consumable
A sterile envelope (Civco #610-542) is placed around
the probe to create a reservoir that will be filled by a
liquid (Ablasonic®; EDAP TMS, Vaulx-en-Velin, France)
ensuring ultrasonic coupling and the transductor’s cool-
ing. The O-ring seal keeps the balloon in place and
ensures the reservoir is sealed. The single-use LivKit is
installed on the HIFU system before each treatment.
During treatments, the transducer is cooled using a
continuous flow of Ablasonic® at 10 °C at a rate of
0.3 L/min. A peristaltic Masterflex pump (L/S model
7518; Cole-Parmer Instruments Co., Chicago, IL,
USA) drives the water around the closed cooling
circuit of the Livkit.
The LivKit contains:
– 350 mL of Ablasonic®
– One set of flexible pipes
Surgical procedure
Anaesthesia will be performed according to standard
procedure. Central venous pressure (CVP) will be mea-
sured immediately before and after the transection. No
Fig. 1 CONSORT flowchart
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pharmacological intervention (such as a diuretic) and no
surgical procedure (such as infra-hepatic inferior vena
cava clamping) will be used to modify the CVP.
The procedure begins with a full exploration of the
abdominal cavity, liver palpation and intra-operative
ultrasound to confirm the indication of liver resection.
Hepatectomy will be carried out in the same way in the
two study arms. In arm A, hepatectomy will be
performed after pre-coagulation of the hepatic paren-
chyma by HIFU along the section plane. This will be the
only difference between arm A and arm B. Whenever
possible, selective control of inflow will be performed.
Otherwise, the Pringle manoeuvre will be used if haemor-
rhage of more than 500 mL occurs during hepatectomy.
In arm A, pre-coagulation is intended to establish a
defined full-thickness plane of coagulative necrosis. This
is generally achieved by six to ten side-by-side 40-s
HIFU ablations, though more can be used if necessary.
Resection is performed in the middle of the pre-
coagulated zone.
In both arms, parenchymal division will begin along
line marked by electrocautery and then cut with
scissors. Liver resection technique (the same for both
groups) uses a Kelly clamp claw, a suction device, a
bipolar forceps and metallic clips. Blunt clamp dissec-
tion is a rapid, easy and cheap method. In essence, a
large Kelly clamp is used to crush the liver paren-
chyma. The relatively soft liver substance dissects
away, leaving behind the vascular and biliary struc-
tures, which are then ligated by vascular clips.
In arm A, it is planned that all vessels < 5 mm in
diameter are sealed successfully using HIFU pre-
coagulation and will not require any additional haemo-
stasis. Surgical clips will be used only to control the few
vessels > 5 mm in diameter.
After completion of liver parenchyma section and
removal of the resected liver, the surgeon will complete
haemostasis of the raw surface of the remaining liver.
This haemostatic phase will be performed only with
Prolene® stitches (Ethicon Inc., Cornelia, GA, USA), or
coagulation with electrocautery, bipolar forceps or
Argon beam coagulator.
Any use of special haemostatic products [such as
Tachosil® (Takeda Pharmaceutical Company Limited,
Osaka, Japan) or biological glue] will be noted.
Blood loss volume during this phase of haemostasis
will be measured and added to the previous blood loss
(during the transection phase) for evaluation of the
primary endpoint.
Data collection and follow-up
Screening/baseline assessments include general demog-
raphy and relevant medical history, including prior/con-
comitant therapies and tumour assessment within the
4 weeks before randomization; complete physical exam-
ination and laboratory tests within 7 days before
randomization. The SPIRIT flowchart of the trial can be
found in Fig. 2. Outcomes will be blindly assessed,
except for intra-operative measures.
All patients included will be followed up in accordance
with the guidelines for patients operated on for CRC LM
for up to 6 months post-surgery.
Statistical considerations
Sample size
The study is powered to detect a clinically meaningful
reduction in blood loss during hepatectomy in patients
with LM. Assuming a blood loss of 7.6 +/− 3.7 mL/cm2
in arm B (data based on our own experience), the study
will have 85% power to detect a twofold decrease of
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age≥ 18 years History of previous major hepatic surgery (i.e. more than three liver
segments) or biliary major surgery (except gall-bladder surgery by
laparoscopy if more than 6 months previously)
Patients with liver metastases requiring a hepatectomy of≥ 2 segments Patients with cirrhosis or sinusoidal obstruction syndrome with
portal hypertension
Eastern Cooperative Oncology Group performance status≤ 1 Pregnant women
Adequate bone marrow and liver function at baseline (defined by platelet
count≥ 100 × 109/L, and haemoglobin of≥ 9 g/dL, and total bilirubin≤
1.5 × upper limit of normal, and transaminases≤ 5× upper limit of normal)
Recovered from prior anti-neoplasic treatment-related toxicity (grade <2
persistent treatment-related toxicity as per Common Terminology Criteria
for Adverse Events v4 are accepted
Willingness for follow-up visits
Covered by a medical insurance
Signed and dated informed consent indicating that the patient has been
informed of all aspects of the trial prior to enrolment
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blood loss in arm A using a Wilcoxon (Mann-Whitney)
rank-sum test with a 0.05 two-sided significance level.
Twenty-one randomized patients per arm are required,
corresponding to a sample size of 42 patients. Due to
the occurrence of potential contraindications to hepatec-
tomy between enrolment and randomization at the
beginning of surgery, up to 8 patients may be enrolled in
addition to the 42 planned. Indeed, the expected overall
number of recruited patients is 50, with an enrolment
period of 24 months and an additional follow-up of
6 months after randomization of the last patient.
Analysis populations
The three following populations will be defined for
statistical analysis:
 The intent-to-treat (ITT) population includes all
randomized patients.
Fig. 2 SPIRIT flowchart
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 The per protocol (PP) population will consist a subset
of patients in the ITT population and includes all
patients with no major protocol violation for inclusion
and non-inclusion criteria and who are compliant
with requirements of the study protocol.
 The safety population includes all patients who
underwent the surgery.
All protocol deviations leading to exclusion from the ITT
to the PP population will be detailed in the analysis plan.
Statistical analyses
Qualitative variables will be described using frequency
and percentage distributions. The number of missing
data will be given, but will not be considered for the
calculation of proportions.
Quantitative data will be described using the number
of observations, mean, standard deviation, median,
minimum and maximum values.
Patient characteristics and other baseline data (demo-
graphics, disease characteristics, clinical and biological
data) will be summarized. The date of randomization
will serve as a reference for calculation of durations un-
less otherwise indicated.
All analyses will be performed using the SAS software
v9.1 (SAS Institute Inc., Cary, NC, USA).
The primary endpoint will be analysed for the ITT and
PP populations.
A Wilcoxon (Mann-Whitney) rank-sum test will be
used to compare the normalized blood loss distribu-
tion between the two arms at a 5% level in a two-
sided situation.
For secondary endpoints, data will be compared be-
tween the two arms using a Wilcoxon (Mann-Whitney)
rank-sum test. The rate of positive margin and the rate
of local recurrence will be summarized by a proportion
together with their 95% confidence interval. Post-
operative complications will be described by study arm
and compared using a Pearson’s chi2 test or a Fisher’s
exact test, if adequate.
Data entry and data management
The sponsor (Centre Léon Bérard) will perform the
study monitoring and will help the investigators to con-
duct the study in compliance with the clinical trial
protocol, Good Clinical Practice (GCP) and local law
requirements.
Data will be entered by investigators on the case re-
port form (CRF). All data will be computerised to detect
missing, out-of-range and inconsistent data. Enquiries
will be made in the case of erroneous and missing data.
Query forms will be sent to the investigators and will be
completed in compliance with source data, initialled,
dated and sent back to the coordinating centre
(Department of Clinical Research of our institution) in
charge of data management.
A patient file will be validated once no more inconsist-
ency is detected by the program.
All database modifications will be recorded in the audit
trail. The database will be submitted to quality control.
Adverse events will be coded according to the Medical
Dictionary for Regulatory Activities (MedDRA®, MSSO,
McLean, VA, USA). The database will be locked after all
queries are solved, and after data review and final validation.
Computerised management of collected data will be
performed by the Department of Clinical Research, using
specific tools developed by the Clininfo SA society
(Lyon, France).
The sponsor is the owner of all collected data and
reports.
Trial Steering Committee
A steering committee will be composed of sponsor rep-
resentatives (project manager and statistician manager),
the principal investigator and other external participants,
as needed. Meetings are scheduled every 3 months from
the beginning of the trial. On an ongoing basis, the
Steering Committee will review each event that could
modify the benefit risk ratio of the study (i.e. scientific,
safety, ethics events), all grade ≥ 3 adverse events and
adverse events of special interest. Additional meetings
may be called at any time if an event occurs or upon
request of any members.
The steering committee will be regularly informed of
the accrual rate of inclusion and of any emergent prob-
lems and will review the activity and safety data
throughout the study.
Independent Data Safety Monitoring Board (iDSMB)
An independent Data Safety Monitoring Board (iDSMB)
is convened by the sponsor and composed of experts in
the field of liver surgery. Data analyses will be supplied
in confidence to the iDSMB, which will be asked to give
advice on whether the accumulated data from the trial,
together with the results from other relevant research,
justifies the continuing recruitment of further patients.
This committee will meet to review each event that
could modify the benefit risk ratio of the study (i.e.
scientific, safety, ethics events). Meetings are scheduled
after the treatment of the first 6 (2 × 3), 12 (2 × 6) and
24 (2 × 12) randomized patients, respectively, to evaluate
the safety of the experimental surgical procedure.
Additional meetings may be called at any time if an
event occurs or on request by one or more members.
The iDSMB will also be regularly informed of the
accrual rate of inclusion, each safety issue, and of any
emergent problems.
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Discussion
Hepatic resection techniques have been improved using
devices such as bipolar forceps, water jet dissectors,
ultrasonic cutting systems, and Argon coagulation.
These techniques are both expensive and time consum-
ing. Recently, new approaches have been developed to
allow bloodless hepatic resection without any vascular
exclusion using energy sources such as radiofrequency,
ultrasonic scalpels, and microwave coagulation [28–32].
Among these alternative techniques, the use of HIFU
has potential advantages.
Preclinical study has demonstrated that HIFU-AR
using the new toroidal-shaped transducer during an
open procedure in an animal model is safe, reduces
bleeding, and can be guided by real-time ultrasound
imaging. This work demonstrated blood loss reduction
during hepatic resection without the Pringle manœuvre
(hepatic pedicle clamping). This was avoided where
possible to prevent liver ischemia–reperfusion injury,
which is known to predispose patients to post-operative
liver failure. In addition, it showed the feasibility, safety,
and reproducibility of HIFU-AR during an open proced-
ure. This technique also holds promise in human
patients for whom pre-coagulation may offer better con-
trol of blood loss, especially in a liver fragile following
chemotherapy. Patients undergoing iterative hepatic
resection might also benefit from HIFU pre-coagulation.
The sample size was calculated to have a twofold
decrease in blood loss, because we consider this twofold
decrease clinically relevant and in accordance with the
results observed in the preclinical study (11.35 mL/cm2
versus 4.77 mL/cm2). The value chosen for the sample
size calculation (7.6 mL/cm2 in the control arm) is in
the upper limit of reported blood loss in the literature. It
is based on personal data when measuring blood loss
was determined by aspirated fluid and also by weighing
all blood-soaked surgical mops, which is essential, other-
wise blood loss might be underestimated.
In the protocol outlined above, the risks are limited
since the surgical procedure is identical to the one pa-
tients would undergo if not randomized to HIFU-AR.
The only difference is that HIFU ablations are carried
out on the section plane of the liver. These ablations will
be performed only after final checking of the indication
for them and immediately before the section phase. The
duration of the HIFU ablations will last between 5 and
7 minutes. We consider that this minor increase in
operative time will be compensated for by a major de-
crease in the time necessary to perform liver transection
and haemostasis. A potential risk for HIFU-AR patients
would be an injury to neighbouring organs secondary to
HIFU ablations. Measures taken to avoid this include
surgical mops placed under the targeted area to limit
risks of ultrasound propagation. Furthermore, this risk
was fully assessed during the phase I and IIa studies re-
cently completed and no adverse effects were observed.
The post-operative follow-up period will last 6 months,
which seems to be sufficient to cover late adverse events.
The study participants in the HIFU-AR group can
expect to benefit from reduced blood loss and a de-
creased period of ischemia in the future liver remnant.
Based on previous preclinical and clinical experience,
the proposed study design, and the safety monitoring plan
described in this protocol, the sponsor considers that
adequate risk mitigation measures are included in this
protocol and that the benefit-risk profile is favourable.
To limit biases, blood losses are normalized by the
resected hepatic area (in square centimetres), which
allows to perform several types of anatomical hepatec-
tomy. We also use stratification by surgeon to ensure
equal allocation of subgroups of participants (i.e. to each
surgeon) in each arm. The three surgeons (AD, MR, PP)
are trained with the HIFU prototype, as they already use
it in an ongoing study [27].
If the results of this study appear clinically relevant, the
development of this technique could be an important im-
provement in treatment of LM by reducing the invasiveness
of surgery. The next step of our research programme is to
improve the user interface and then to evaluate the HIFU
device in a multicentre phase III study. It may also be pos-
sible to extend HIFU-AR to other types of liver resection
such as segmentectomy or non-anatomic resections and to
primary liver tumours. Furthermore, combining HIFU-AR
with HIFU ablation of non-resectable metastases may per-
mit an increase in liver surgery with curative intent for pa-
tients with non-resectable LM.
Trial status
The trial started recruitment in May 2016. The trial is
expected to be completed by December 2018.
Additional file
Additional file 1: SPIRIT checklist. (DOC 120 kb)
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